The stock of Foundation Medicine Inc (NASDAQ:FMI) is a huge mover today! The stock increased 4.58% or $1.05 on November 23, hitting $24. About 144,969 shares traded hands. Foundation Medicine Inc (NASDAQ:FMI) has risen 36.29% since April 22, 2016 and is uptrending. It has outperformed by 30.88% the S&P500.
The move comes after 5 months positive chart setup for the $848.80 million company. It was reported on Nov, 24 by Barchart.com. We have $24.96 PT which if reached, will make NASDAQ:FMI worth $33.95M more.
Analysts await Foundation Medicine Inc (NASDAQ:FMI) to report earnings on February, 28. They expect $-1.00 earnings per share, down 81.82% or $0.45 from last year’s $-0.55 per share. After $-0.90 actual earnings per share reported by Foundation Medicine Inc for the previous quarter, Wall Street now forecasts 11.11% negative EPS growth.
Foundation Medicine Inc (NASDAQ:FMI) Ratings Coverage
Out of 8 analysts covering Foundation Medicine (NASDAQ:FMI), 0 rate it a “Buy”, 0 “Sell”, while 8 “Hold”. This means 0 are positive. Foundation Medicine has been the topic of 10 analyst reports since July 30, 2015 according to StockzIntelligence Inc. As per Wednesday, September 21, the company rating was maintained by UBS. The rating was downgraded by BTIG Research on Wednesday, November 4 to “Neutral”. The rating was downgraded by Wells Fargo on Wednesday, September 16 to “Market Perform”. The firm earned “Buy” rating on Monday, September 14 by BTIG Research. The stock of Foundation Medicine Inc (NASDAQ:FMI) earned “Hold” rating by Benchmark on Thursday, November 3. The stock of Foundation Medicine Inc (NASDAQ:FMI) has “Market Perform” rating given on Thursday, July 30 by JMP Securities.
According to Zacks Investment Research, “Foundation Medicine, Inc. provides molecular information products primarily in the United States. The company offers FoundationOne(TM) a molecular information product for the analysis of routine cancer specimens in a clinical setting. Its molecular information platform generates actionable genomic information about a patient’s individual disease, enabling physicians to optimize treatments in clinical practice, and enabling biopharmaceutical companies to develop targeted oncology therapies. Foundation Medicine, Inc. is based in Cambridge, Massachusetts.”
Insitutional Activity: The institutional sentiment decreased to 1.67 in Q2 2016. Its down 0.10, from 1.77 in 2016Q1. The ratio dived, as 10 funds sold all Foundation Medicine Inc shares owned while 16 reduced positions. 4 funds bought stakes while 42 increased positions. They now own 10.32 million shares or 3.75% less from 10.73 million shares in 2016Q1.
Northern Tru accumulated 0% or 160,235 shares. The Maryland-based Price T Rowe Md has invested 0% in Foundation Medicine Inc (NASDAQ:FMI). Blackrock Group Inc Limited accumulated 3,451 shares or 0% of the stock. Whittier Tru Of Nevada last reported 784 shares in the company. Royal Bank & Trust Of Canada has invested 0% of its portfolio in Foundation Medicine Inc (NASDAQ:FMI). Lord Abbett & Communications Limited Liability Com holds 0.01% of its portfolio in Foundation Medicine Inc (NASDAQ:FMI) for 210,912 shares. Blackrock Inv Mgmt Lc accumulated 0% or 49,186 shares. Group One Trading L P accumulated 304,651 shares or 0.07% of the stock. Blackrock Advisors Limited Liability Company has 6,107 shares for 0% of their US portfolio. The Kansas-based Creative Planning has invested 0% in Foundation Medicine Inc (NASDAQ:FMI). Gilder Gagnon Howe & Ltd Llc has invested 0.75% of its portfolio in Foundation Medicine Inc (NASDAQ:FMI). Platinum Mgmt Ltd holds 0.06% or 128,000 shares in its portfolio. Deutsche Bank Ag has invested 0% of its portfolio in Foundation Medicine Inc (NASDAQ:FMI). Zurcher Kantonalbank (Zurich Cantonalbank) accumulated 0.03% or 122,264 shares. Ipswich Inv Mngmt Co holds 0.2% or 21,800 shares in its portfolio.
More news for Foundation Medicine Inc (NASDAQ:FMI) were recently published by: Businesswire.com, which released: “Foundation Medicine Announces Commercial Launch of Liquid Biopsy Assay …” on May 03, 2016. Businesswire.com‘s article titled: “Foundation Medicine Adds New Immunotherapy Features to Its Market-Leading Products” and published on August 22, 2016 is yet another important article.
FMI Company Profile
Foundation Medicine, Inc., incorporated on November 12, 2009, is a molecular information company. The Firm sells products that are enabled by its molecular information platform to physicians and biopharmaceutical companies. The Company’s segment is the business of delivering molecular information about cancer to its customers. The Company’s platform includes various methods and algorithms for analyzing specimens across various types of cancer, and for incorporating that information into clinical care. The Company’s products provide genomic information about each patient’s individual cancer, enabling physicians to optimize treatments in clinical practice and biopharmaceutical companies to develop targeted oncology therapies. The Company’s flagship clinical molecular information products, FoundationOne for solid tumors, and FoundationOne Heme for blood cancers or hematologic malignancies, including leukemia, lymphoma, myeloma and advanced sarcomas, are genomic profiles designed for use in the routine care of patients with cancer.
Receive News & Ratings Via Email - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings with our FREE daily email newsletter.